The present invention is related to synthesis routes to obtain the compound propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide (formula 1).
The synthesis of the compound of formula (1) has been described before in WO 2007002433 and WO 2007002325.
However, the known synthesis routes may not be readily adapted for use on an industrial scale.
The present invention relates in part to a process for the manufacture of the compound of formula (1),
comprising the steps of reacting the compound of formula (5),
with 4-chlorophenylboronic acid in the presence of a palladium catalyst to produce the compound of formula (6),
and cleaving the 2,6-dichlorobenzamide group in said compound of formula (6) to produce the compound of formula (1).
The present invention also relates in part to a compound of formula (A),
The present invention further relates in part to a compound of formula (B)
In addition, the present invention relates to a composition comprising the compound of formula (1) and the compound of formula (B).
The present invention also relates to an analytical method for the detection of whether the process as described above has been used in the manufacture of the compound of formula (1), said method comprising obtaining a sample from a medicament primarily containing the compound of formula (1) as active ingredient, and applying a suitable analytical method in order to detect whether said sample contains the compound of formula (B), wherein the presence of any amount of the compound of formula (B) indicates that the process has been used.
The present invention further relates to a process for the manufacture of compound (I),
comprising the steps of:
with the compound of formula (III),
in the presence of a catalyst, copper(I)iodide and a base, to produce the compound of formula (IV),
and
In addition, the present invention relates to a compound of formula (IV),
wherein
The present invention provides new and improved synthesis routes for the compound of formula (1), which employ reaction conditions which are particularly amenable to being carried out on an industrial scale.
According to the present invention, there is provided a process for the manufacture of the compound of formula (1),
comprising the steps of reacting the compound of formula (5),
with 4-chlorophenylboronic acid (5a, scheme 1) in the presence of a palladium catalyst to produce the compound of formula (6),
and
The process according to the present invention efficiently uses starting materials, avoids formation of high quantities of undesirable by-products, provides high throughput and good product yields and can safely be carried out in large scale production. It is also less expensive, and, due to the efficient use of starting materials, environmentally friendlier than processes disclosed in the prior art.
The term “palladium catalyst” as used herein means any suitable palladium (Pd) catalyst, preferably bis(triphenylphosphin)palladium(II)dichloride ((PPh3)2PdCl2) and Pd on charcoal. Preferably, the amount of (PPh3)2PdCl2 is about 0.0025 equivalents with respect to compound of formula (5).
The compound of formula (5) can be obtained according to methods known to the person of skill in the art of organic chemistry. In a particularly preferred embodiment according to the present invention, the compound of formula (5) is obtained by reacting the compound of formula (2),
with a suitable activating agent (e.g., oxalylchloride ((COCl)2)) to produce the corresponding acid chloride, then reacting said acid chloride with 5-Bromo-7-azaindole (formula 3) and a suitable coupling agent (e.g., aluminium trichloride) to produce the compound of formula (4)
and reacting said compound of formula (4) with 2,6-dichlorobenzoylchloride under conditions suitable to produce the compound of formula (5).
In another particularly preferred embodiment according to the present invention there is provided the process for the manufacture of the compound of formula (1), wherein
a) the compound of formula (2)
is reacted in a suitable solvent (e.g., methylenechloride (CH2Cl2)) with a suitable activating agent (e.g., Vilsmeier's salt prepared in situ from oxalylchloride ((COCl)2 and N,N-Dimethylformamide (DMF)) to produce the corresponding acid chloride, then reacting said acid chloride with 5-bromo-7-azaindole (formula 3) in the presence of a suitable activating agent (e.g., aluminium trichloride) to produce the compound of formula (4),
b) reacting said compound of formula (4) i with 2,6-dichlorobenzoylchloride in the presence of a suitable base (e. g. n-Tripropylamine (n-Pr3N)) and suitable catalyst (e.g. N,N-Dimethylaminopyridine (DMAP)) to produce the compound of formula (5),
c) reacting said compound of formula (5) with 4-chlorophenylboronic acid in the presence of a suitable palladium catalyst (e.g., (PPh3)2PdCl2) to produce the compound of formula (6)
and
d) reacting said compound of formula (6) with ammonia (NH3) or a primary or secondary amine (e.g. dimethylamine) in an alcohol (methanol or ethanol) solution diluted with a polar aprotic solvent like DMA to produce the compound of formula (1).
In a preferred embodiment according to the present invention, the above-mentioned reaction step c) is carried out in a 2 phase reaction mixture comprising a non-polar aprotic solvent such as anisole or toluene and aqueous sodium or potassium carbonate (Na2CO3, K2CO3).
The compounds (4), (5) and (6) are novel and each form an embodiment of the present invention.
The process according to the present invention can be summarized according to the following reaction scheme (scheme 1) wherein, unless explicitly otherwise stated, all abbreviations and expressions have the meanings well known to the person of skill in the art of organic chemistry. All reaction partners and auxiliary agents (like i.e. catalysts, solvents) are commercially available.
According to the present invention, the first reaction under step a) is the formation of an acid chloride of the carboxylic acid of formula (2). The reaction can be carried out employing a suspension of the compound of formula (2) in suitable medium, e.g., methylenechloride (CH2Cl2) containing catalytic amounts of DMF, to which a solution of oxalylchloride ((COCl)2) in CH2Cl2 is slowly added. The addition is typically carried out at room temperature (RT) and the reaction mixture is further stirred at RT until reaction completion (ca 6h). The next reaction is a Friedel-Crafts-Acylation. The freshly obtained solution of acid chloride is added into a cooled (T=−12 to 5° C., preferably 0-5° C.) suspension of AlCl3 and 5-Bromo-7-azaindole (3) in CH2Cl2. The reaction mixture is allowed to heat up till RT due to released heat of the exothermic reaction and stirred for about 8h to complete the reaction. The work-up and isolation procedure involves pouring of the reaction mixture into iced water, followed by extractive work-up and crystallization of the compound of formula (4) from THF/methylenchloride/heptane. The compound of formula (4) can be further purified by washing with i.e. heptane.
Reaction step b) starts with the preparation of a suspension of the compound of formula (4) in a suitable aprotic solvent (e.g., toluene). Subsequently dimethylaminopyridine (DMAP), n-tripropylamine and 2,6-dichlorobenzoylchloride are added at RT. The reaction mixture is stirred for about 60 minutes. After completion of the reaction an aqueous work-up is performed. Subsequently the toluene is slowly evaporated from the organic solution, leading to the crystallization of the compound of formula (5) which can finally be isolated and further purified through additional washing with e.g., cooled toluene.
Reaction step c) is a Pd-catalyzed Suzuki-coupling reaction of the compound of formula (5) with 4-chlorophenylboronic acid (5a). The reaction starts with the preparation of a suspension of 4-chlorophenylboronic acid (5a) and the compound of formula (5) in an aprotic solvent, such as anisole, to which an aqueous solution of Na2CO3 is added. The reaction mixture is heated slowly up to a temperature of about 85° C. During heating the Pd-catalyst is added at a temperature between RT and around 70° C. Any suitable Pd-catalyst can be used, with bis(triphenylphosphin) palladium(II)dichloride ((PPh3)2PdCl2) being especially preferred. The reaction mixture is stirred for about 120 minutes at a temperature of about 85° C. to complete the reaction. The hot bi-phasic reaction mixture is filtered to remove potentially precipitated Pd. After aqueous work-up the organic (anisole) phase is concentrated by evaporation, diluted with methanol and cooled down to about 0° C. in order to initiate crystallization of the compound of formula (6). The precipitate is isolated, washed several times with cooled methanol and subsequently dried in vacuum. If needed the compound of formula (6) can be further purified by re-crystallization from Toluene.
Reaction step d) is the removal of the 2,6-dichlorobenzamide protection group. The reaction is carried out in a suspension/solution of the compound of formula (6) in DMA/methanol (about 1:1-2:1) by addition of about 3-7 equivalents of a saturated ammonia solution (NH3 in Methanol) at RT. The reaction mixture is stirred at about 55° C. until the protection group is entirely cleaved (about 10 h). The resulting solution is diluted with methanol and subsequently the ammonia is removed via azeotropic distillation under reduced pressure. The residue is diluted with methanol and cooled to RT in order to initiate crystallization of the compound of formula (1) which can then be isolated from the reaction mixture by filtration. The compound of formula (1) can be further purified by washing with e.g., methanol.
In another embodiment of the present invention there are identified specific compounds (compounds (A) and (B) as specified below) which are by-products of the present synthesis method.
The compound of formula (A) may be formed during the reaction of the compound of formula (5) with 4-Chlorophenylboronic acid (step c), scheme 1). The compound of formula (B) is the de-protected form of formula (A) as obtained during reaction step d) as defined above (see also scheme 1). These compounds, in particular the compound of formula (B) can serve as characteristic fingerprints for the use of the present process.
Trace amounts of the compound of formula (B) are typically found in the final product (formula (1)) as a pharmaceutically acceptable impurity in an amount of less than 0.30%, and usually in an amount of from about 0.02% to about 0.15%, as identified by HPLC, provided said compound of formula (1) had been synthesized according to the present method. Therefore, while the impurity/trace amounts of the compound of formula (B) will not affect the pharmacological- or toxicity profile of any potential future medicament or pharmaceutical preparation containing the compound of formula (1), said compound may nevertheless serve as a fingerprint in order to detect whether the present process has been used to manufacture the compound of formula (1). The presence of the compound of formula (B) will therefore allow for an unambiguous identification as to whether the present process has been used in the manufacture of the compound of formula (1).
The compounds of formulas (A) and (B), in particular the compound of formula (B), may be detected in amounts of from about 0.02% to about 0.15% by weight in a composition which otherwise contains >99% by weight of the compound of formula (1) formed using the process according to the present invention, and even following conventional purification methods known to the person of skill in the art. Therefore, trace amounts of the compound of formula (B) may even be detectable in pharmaceutical preparations containing the compound of formula (1) when obtained according to the present process. The compounds of formula (A) and (B) show the following NMR signals:
Compound A:
1H-NMR (500 MHz, d6-DMSO): δ0.99 (t, J=7.5 Hz, 3H), 1.72-1.82 (m, 2H), 3.15-3.21 (m, 2H), 7.37 (t, J=9.0 Hz, 1H), 7.52-7.58 (m, 2H), 7.65-7.74 (m, 4H), 7.76-7.85 (m, 4H), 7.87-7.92 (m, 2H), 8.58 (br. s, 1H), 8.82 (d, J=2.5 Hz, 1H), 8.90 (br. s, 1H), 9.85 (br. s, 1H).
Compound B:
1H-NMR (600 MHz, d6-DMSO): δ0.97 (t, J=7.5 Hz, 3H), 1.70-1.80 (m, 2H), 3.10-3.15 (m, 2H), 7.29 (t, J=8.7 Hz, 1H), 7.54-7.63 (m, 3H), 7.78-7.82 (m, 2H), 7.83-7.90 (m, 4H), 8.25 (s, 1H), 8.70 (br. s, 1H), 8.79 (d, J=1.8 Hz, 1H), 9.78 (br. s, 1H), 13.02 (br. s, 1H).
Therefore, as a further embodiment according to the present invention, there are provided the compounds of formulae (A) and (B) as such.
In yet another embodiment the present invention provides an analytical method for detecting whether the process according to the present invention has been used, characterized in that detectable levels of the compounds of formula (A) and/or (B) as disclosed herein are generally present in any commercial pharmaceutical preparation comprising primarily the compound of formula (1) prepared employing the synthetic process disclosed herein. Preferably the analytical method is used to detect the compound of formula (B). Any suitable analytical method known to the Organic Chemist may be applied, such as for example IR-spectroscopy, NMR-spectroscopy, Mass Spectrometry (MS) or High Performance Liquid Chromatography (HPLC). More preferably the analytical method is based on High Performance Liquid Chromatography (HPLC), which may optionally be combined with a second analytical method such as for example MS (HPLC-MS).
An aspect of the present invention is an analytical method for the detection of whether the process described above has been used in the manufacture of the compound of formula (1), said method comprising obtaining a sample from a medicament primarily containing the compound of formula (1) as active ingredient, and applying a suitable analytical method in order to detect whether said sample contains the compound of formula (B), wherein the presence of any amount of the compound of formula (B) indicates that said process has been used.
The compound of formula (1) shows potential as an active pharmaceutical ingredient, as inter alia described in WO 2007002433 and WO 2007002325. Consequently, in a further embodiment of the present invention, there is provided a pharmaceutical preparation comprising the compound of formula (1) together with detectable amounts of at least compound of formula (B). More particularly there is provided a composition comprising the compound of formula (1) in an amount greater than 99% by weight and the compound of formula (B) in amounts from about 0.01% to about 0.15% by weight. Said composition may be further processed with pharmaceutically acceptable adjuvants to give any kind of pharmaceutical preparations as inter alia described in WO 2007002433 and WO 2007002325.
The starting materials, solvents, catalysts and auxiliary reagents used in the method according to the present invention (see i.e. scheme 1) are commercially available. However, when produced on a large industrial scale, there remains a need to also obtain large amounts of starting materials in good quality and high yields.
Consequently, according to the present invention, there are also provided improved methods of making azaindole derivatives which are halogenated at their 5-position, in particular 5-bromo-7-azaindole ((3), CAS 183208-35-7) and 5-chloro-7-azaindole (CAS 866546-07-8). 5-Bromo-7-azaindole is a useful starting material in the above-mentioned process according to scheme 1.
Consequently, in a further embodiment according to the present invention there is provided a process for the manufacture of compound (I),
comprising the steps of:
with the compound of formula (III),
in the presence of a catalyst, copper(I)iodide and a base, to produce the compound of formula (IV),
and
In one particularly preferred embodiment according to the present invention, the above process aa) to cc) is carried out with X being —Br.
In another particularly preferred embodiment according to the present invention, the above process aa) to cc) is carried out with X being —Cl.
In still another preferred embodiment according to the present invention R1 and R2 are both methyl.
The synthesis of compounds of formula (I) as described above is a sequential process. After each reaction described in steps aa) to cc), aqueous work-up procedures are applied and the formed intermediate product is optionally being isolated. In an alternative setup it is also possible to carry out the reaction steps bb) and cc) almost simultaneously. This means the conversion of compound (V) into compound (I) starts as soon as compound (V) is formed, and before the reaction to obtain compound (V) (step bb)) is terminated. Therefore, the two reaction steps bb) and cc) may run under the same reaction conditions. Consequently, no work-up of compound (V) prior to its further reaction to compound (I) is required according to this alternative method.
Therefore, in yet another embodiment there is provided a method to obtain the compound of formula (I) directly from formula (IV) without the need to apply an aqueous work-up on the stage of the compound of formula (V). This can be achieved by adding to the compound of formula (IV), dissolved in an approximately 1:1 (w/w) mixture of water and N-methylpyrrolidone (NMP), 5 to 10 equivalents of aqueous sodium hydroxide at about 75 to about 85° C. while applying a pressure of about 350 mbar, followed by stirring at about 75 to about 85° C. and under reduced pressure (<400 mbar) for 15 to 20 hours. During the entire reaction time distilled acetone/water is continuously replaced by water. The termination of the reaction can be monitored by taking a sample out of the reaction mixture after 15 to 20 hours and analyzing said sample with HPLC. A specific procedure for this reaction is disclosed in Example 7b.
The term “C1-C4 alkyl” as used herein means a linear or branched saturated hydrocarbon, such as for example methyl, ethyl, propyl, i-propyl, n-butyl, 2-butyl, tert-butyl, with methyl being especially preferred.
The term “alkali metal hydroxide” as used herein means sodium-, lithium- or potassium hydroxide, with lithium- and sodium hydroxide being especially preferred.
The term “reduced pressure” as used herein means <500 mbar, preferably <400 mbar.
The term “catalyst” as used herein in step aa) means any Pd(II)- or Pd(0)-catalyst usually used in this type of Sonogashira reaction. Examples of such catalysts are Pd(PPh3)4, PdCl2(PPh3)2, Pd(OAc)2, Pd2(dba)3 with bis-(triphenylphosphine)-palladium(II)-dichloride (PdCl2(PPh3)2) being especially preferred.
The term “base” as used herein in step aa) means weak bases as for example N-methylmorpholine or trialkyl-amines, with triethylamine being especially preferred.
The term “strong base” as used herein in step cc) means alkali metal alcoholates, preferably potassium tert.-butylate.
In an embodiment of the invention, step bb) is carried out under reduced pressure below 100 mbar.
In an embodiment, the catalyst in step aa) is PdCl2(PPh3)2 and the alkali metal hydroxide in step bb) is lithium- or sodium hydroxide.
In an embodiment, the compound of formula (IV) is dissolved in a mixture of water and N-methylpyrrolidone, and is reacted in the presence of aqueous sodium hydroxide at about 75 to about 85° C. and under reduced pressure for 15 to 20 hours to give directly the compound of formula (I) without the need to apply an aqueous work-up of the compound of formula (V).
In a particularly preferred embodiment according to the present invention, the above-mentioned reaction step aa) is carried out in the presence of bis-(triphenylphosphine)-palladium(II)-dichloride, copper(I)iodide and triethylamine, the reaction step bb) is carried out with aqueous lithium- or sodium hydroxide and the reaction step cc) is carried out in the presence of potassium tert.-butylate or aqueous sodium hydroxide. The elimination of acetone (step bb) and subsequent ring formation of step cc) are preferably carried out in N-methylpyrrolidone or in a mixture of N-methylpyrrolidone and water as solvent.
The process according to the reaction steps aa) to cc) is preferably carried out according to the specific conditions and parameters given in Example 7a) or b). Consequently, the specific process according to Example 7a) or b) form each another preferred embodiment according to the present invention.
The compounds of formula (II) can be obtained for example by iodination of the corresponding 5-halogenated 2-amino-pyridines. Among the many iodination conditions known to the skilled in the art a mixture of iodine and periodic acid proved to be especially suitable for the mentioned transformation.
The above described synthesis route via the compound of formula (IV) is a novel, alternative method for the production of the otherwise well known compounds of formula (I), in particular the 5-bromo-7-azaindole (3). A particular advantage of this process is the use of the intermediate compound of formula (IV) which can be easily purified and isolated from the reaction mixture. In addition, the use of compound (IV) avoids the release of environmentally hazardous Si by-products upon cyclization, which are formed if the corresponding trimethylsilyl-ethynyl derivative is used, which is usually known for this type of reaction (Sonogashira reaction) as inter alia described in WO 2009/016460 and US 2006/0183758.
The compounds of formula (IV) are thus valuable and novel intermediates in the above-described synthesis to obtain 5-halogenated 7-azaindoles (I). Therefore, in yet another embodiment according to the present invention there is provided the compounds of formula (IV) as such.
The present invention is now illustrated by the following accompanying working examples. In some examples, the term “In-process control” is used. This term means that a sample is taken from the reaction mixture while the process is running, and said sample is being analyzed by standard techniques known to the skilled person, preferably by HPLC, in order to detect the degree of conversion of starting material into product.
Yield: 85 g (=90%) light beige colored, crystalline azaindole (4).
The reaction mixture was stirred for about 1-2 hours at a temperature between 20-25 ° C., whereby the color of the mixture turned into brown.
The brownish reaction mixture as obtained by the last step above, was diluted with
Yield: 57 g (90%) of compound of formula (5).
Yield: 74-76 g (82-85%) almost colorless, crystalline Chlorophenylbenzamide (6). The product can be optionally re-crystallized from toluene for further purification.
1H-NMR (400 MHz, CDCl3): δ ppm 1.09 (t, J=7.5 Hz, 3H), 1.86-1.99 (m, 2H), 3.10-3.19 (m, 2H), 6.53 (s, 1H), 7.11 (dt, J=8.6, 1.5 Hz, 1H), 7.39-7.49 (m, 5H), 7.50-7.59 (m, 2H), 7.79 (td, J=9.0, 5.6 Hz, 1H), 8.32 (br. s, 1H), 8.43 (br. s, 1H), 8.84 (d, J=2.3 Hz, 1H).
Yield: 49 g (95%) of the white, crystalline compound formula (1).
1H-NMR (600 MHz, CDCl3): δ ppm 1.07 (t, J=7.5 Hz, 3H), 1.84-1.98 (m, 2H), 3.07-3.17 (m, 2H), 6.41 (s, 1H), 7.06 (dt, J=8.6 Hz, 1.5 Hz, 1H), 7.46-7.51 (m, 2H), 7.60-7.64 (m, 2H), 7.70 (td, J=9.0, 5.5 Hz, 1H), 7.73 (d, J=2.7 Hz, 1H), 8.65 (d, J=2.2 Hz, 1H), 8.88 (d, J=1.9 Hz, 1H), 9.55 (br. s, 1H).
Purity: ≧99% (m/m, HPLC); Palladium content ≦5 ppm; compound (B): about 0.1%
Yield: 90.5 g of slightly brownish crystals with an assay of 95.0% (m/m). This corresponds to a corrected yield of 86%.
A suspension of 2-amino-5-bromo-3-iodopyridine (10.0 g, 33.5 mmol), bis-(triphenyl-phosphine)-palladium(II)-dichloride (117 mg, 0.17 mmol), copper(I)iodide (79 mg, 0.41 mmol) and triethylamine (6.1 mL, 43.5 mmol) in dichloromethane (40 mL) was treated at 23 to 30° C. within 1 to 2 hours with a solution of 1,1-dimethyl-2-propyn-1-ol (3.70 g, 44 mmol) in dichloromethane (10 mL) and the resulting mixture was stirred at 25° C. for 3 hours. The mixture was diluted with dichloromethane (20 mL) and washed with water (2×50 mL). The organic phase was then treated with 1 M HCl (80 mL). The layers were separated and the organic layer was extracted with 1 M HCl (20 mL). The combined product containing aqueous layers were washed with dichloromethane (2×10 mL). The pH of the aqueous layer was adjusted to pH 7-9 by the drop wise addition of sodium hydroxide solution (28% in water, 18 g). The resulting suspension was stirred at 20° C. for 2 hours and the crystals were then filtered off and washed with water (2×20 mL). The wet crystals were dried at 50° C./<30 mbar affording 6.99 g (82%) of 4-(2-amino-5-bromo-pyridin-3-yl)-2-methyl-but-3-yn-2-ol as a melted mass with a purity of 99.5% (HPLC, area%). 1H NMR (400 MHz, CDCl3): δ ppm 1.63 (s, 6H); 4.0 (br., 3H); 7.59 (d, J=2.4, 1H); 8.03 (d, J=2.4, 1H).
Yield: 65.04 g (93%) of yellow crystals with a content of 98.6% (m/m).
This intermediate can optionally be re-crystallized from isopropanol/water for further purification.
1H NMR (400 MHz, CDCl3): δ ppm 1.61 (s, 6H); 2.3 (br., 1H); 4.9 (br., 2H); 7.57 (d, J=2.4, 1H); 8.01 (d, J=2.4, 1H).
A suspension of 2-amino-5-bromo-3-iodopyridine (5.0 g, 16.7 mmol), bis-(triphenyl-phosphine)-palladium(II)-dichloride (43 mg, 0.061 mmol), copper(I)iodide (29.4 mg, 0.15 mmol) and triethylamine (2.21 g, 21.8 mmol) in dichloromethane (20 mL) was treated at 23 to 30° C. within 1 to 2 hours with a solution of 1,1-dimethyl-2-propyn-1-ol (1.85 g, 21.7 mmol) in dichloromethane (10 mL) and the resulting mixture was stirred at 25° C. for 4 hours. The mixture was diluted with dichloromethane (10 mL) and washed with water (2×25 mL). The organic phase was then treated with 1 M HCl (40 mL). The layers were separated and the organic layer was extracted with 1 M HCl (15 mL). The combined product containing aqueous layers were washed with dichloromethane (2×8 mL). The pH of the aqueous layer was adjusted to pH 7-9 by the drop wise addition of sodium hydroxide solution (28% in water). The resulting suspension was stirred at 20° C. over night and the crystals were then filtered off and washed with water (2×5 mL). The wet crystals were dissolved in N-methylpyrrolidone (50 mL) and treated within 2 hours at 60° C. and 50-100 mbar with an aqueous solution of lithium hydroxide (2.4 M, 32 mL). The resulting mixture was heated to 75° C. and stirred at this temperature and under reduced pressure (50-100 mbar) for 15-20 hours. Toluene (20 mL) and water (20 mL) were then added and the layers were separated. The aqueous layer was extracted with toluene (3×25 mL). The combined organic layers were washed with water (3×10 mL) and then concentrated to dryness. The residue was dissolved in N-methylpyrrolidone (50 mL) and treated at 60° C. with potassium tert.-butylate (3.52 g, 30.7 mmol). After stirring for 3 hours at 60° C., the mixture was cooled to ambient temperature and diluted with toluene (40 mL) and water (40 mL). The aqueous layer was separated and back extracted with toluene (3×50 mL). The combined toluene layers were washed with water (3×10 mL) and then concentrated to dryness. The residue was dissolved in a hot mixture of toluene and n-heptane (20 mL). The clear solution was cooled to −5° C. within 4 to 6 hours whereupon crystals precipitated. The suspension was stirred at −5° C. for 2-4 hours. The crystals were filtered off, washed with heptane and dried at 45° C./<30 mbars over night to afford 5-bromo-7-azaindole (2.05 g, 62% yield) as slightly yellow crystals with a purity of 99.6% (HPLC, area%).
Yield: 46.5 g (75%) of slightly yellow crystals with an assay of 100.1% (m/m).
Number | Date | Country | Kind |
---|---|---|---|
09167054 | Aug 2009 | EP | regional |
09175101 | Nov 2009 | EP | regional |
This application is a divisional application of U.S. application Ser. No. 12/843,908, filed Jul. 27, 2010, and claims the benefit of European Patent Application No. 09167054.7, filed Aug. 3, 2009, and European Patent Application No. 09175101.6, filed Nov. 5, 2009, both of which are hereby incorporated by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
2234705 | Normington et al. | Apr 1940 | A |
2413258 | Soday | Dec 1946 | A |
3524860 | Alberstson et al. | Aug 1970 | A |
4150949 | Smith | Apr 1979 | A |
4301159 | Ogata et al. | Nov 1981 | A |
4439444 | Nisato et al. | Mar 1984 | A |
4568649 | Bertoglio-Matte | Feb 1986 | A |
4595780 | Ogata et al. | Jun 1986 | A |
4626513 | Burton et al. | Dec 1986 | A |
4634701 | De Vincentiis | Jan 1987 | A |
4714693 | Targos | Dec 1987 | A |
4727395 | Oda et al. | Feb 1988 | A |
4863945 | Friebe et al. | Sep 1989 | A |
5120782 | Hubsch et al. | Jun 1992 | A |
5124335 | Patchett et al. | Jun 1992 | A |
5143854 | Pirrung et al. | Sep 1992 | A |
5338849 | Festal et al. | Aug 1994 | A |
5360822 | Morino et al. | Nov 1994 | A |
5426039 | Wallace et al. | Jun 1995 | A |
5432177 | Baker et al. | Jul 1995 | A |
5434049 | Okano et al. | Jul 1995 | A |
5449614 | Danos et al. | Sep 1995 | A |
5474935 | Chattejee et al. | Dec 1995 | A |
5486525 | Summers et al. | Jan 1996 | A |
5556752 | Lockhart et al. | Sep 1996 | A |
5576319 | Baker et al. | Nov 1996 | A |
5580859 | Felgner et al. | Dec 1996 | A |
5631236 | Woo et al. | May 1997 | A |
5632957 | Heller et al. | May 1997 | A |
5658775 | Gilboa | Aug 1997 | A |
5681959 | Bishop et al. | Oct 1997 | A |
5700637 | Southern | Dec 1997 | A |
5700809 | Leeson et al. | Dec 1997 | A |
5712285 | Curtis et al. | Jan 1998 | A |
5721118 | Scheffler | Feb 1998 | A |
5721246 | Yoshino et al. | Feb 1998 | A |
5744305 | Fodor et al. | Apr 1998 | A |
5747276 | Hoch et al. | May 1998 | A |
5763198 | Hirth et al. | Jun 1998 | A |
5770456 | Holmes | Jun 1998 | A |
5800992 | Fodor et al. | Sep 1998 | A |
5807522 | Brown et al. | Sep 1998 | A |
5830645 | Pinkel et al. | Nov 1998 | A |
5840485 | Lebl et al. | Nov 1998 | A |
5856174 | Lipshutz et al. | Jan 1999 | A |
5858995 | Kawai et al. | Jan 1999 | A |
5877007 | Housey | Mar 1999 | A |
5952362 | Cournoyer et al. | Sep 1999 | A |
5958944 | Arita et al. | Sep 1999 | A |
5959098 | Goldberg et al. | Sep 1999 | A |
5965452 | Kovacs | Oct 1999 | A |
6013440 | Lipshutz et al. | Jan 2000 | A |
6022963 | McGall et al. | Feb 2000 | A |
6025155 | Hadlaczkv et al. | Feb 2000 | A |
6045996 | Cronin et al. | Apr 2000 | A |
6048695 | Bradley et al. | Apr 2000 | A |
6054270 | Southern | Apr 2000 | A |
6090912 | Lebl et al. | Jul 2000 | A |
6096718 | Weitzman et al. | Aug 2000 | A |
6107478 | Pedersen et al. | Aug 2000 | A |
6110456 | Durina | Aug 2000 | A |
6110458 | Freeman et al. | Aug 2000 | A |
6113913 | Brough et al. | Sep 2000 | A |
6117681 | Salmons et al. | Sep 2000 | A |
6161776 | Byles | Dec 2000 | A |
6178384 | Kolossvary | Jan 2001 | B1 |
6235769 | Clary | May 2001 | B1 |
6243980 | Bronstein et al. | Jun 2001 | B1 |
6258606 | Kovacs | Jul 2001 | B1 |
6261776 | Pirrung et al. | Jul 2001 | B1 |
6277489 | Abbott et al. | Aug 2001 | B1 |
6277628 | Johann et al. | Aug 2001 | B1 |
6288234 | Griffin | Sep 2001 | B1 |
6294330 | Michnick et al. | Sep 2001 | B1 |
6310074 | Depreux et al. | Oct 2001 | B1 |
6348474 | Kayakiri et al. | Feb 2002 | B1 |
6350786 | Albano et al. | Feb 2002 | B1 |
6451825 | Masayoshi et al. | Sep 2002 | B1 |
6476045 | Dinnell et al. | Nov 2002 | B1 |
6545014 | Verner | Apr 2003 | B2 |
6653309 | Saunders et al. | Nov 2003 | B1 |
6673812 | Azuma et al. | Jan 2004 | B1 |
6787534 | Haneda et al. | Sep 2004 | B2 |
6858860 | Hosono et al. | Feb 2005 | B2 |
6897207 | Cox et al. | May 2005 | B2 |
7109208 | Takayama et al. | Sep 2006 | B2 |
7122318 | Ono et al. | Oct 2006 | B2 |
7259165 | Bernotas et al. | Aug 2007 | B2 |
7361763 | Arnold et al. | Apr 2008 | B2 |
7361764 | Arnold et al. | Apr 2008 | B2 |
7452993 | Arnold et al. | Nov 2008 | B2 |
7498342 | Ibrahim et al. | Mar 2009 | B2 |
7504509 | Ibrahim et al. | Mar 2009 | B2 |
7582637 | Arnold et al. | Sep 2009 | B2 |
7601839 | Arnold et al. | Oct 2009 | B2 |
7626021 | Arnold et al. | Dec 2009 | B2 |
7846941 | Zhang et al. | Dec 2010 | B2 |
7863288 | Ibrahim et al. | Jan 2011 | B2 |
7863289 | Spevak et al. | Jan 2011 | B2 |
7893075 | Zhang et al. | Feb 2011 | B2 |
7947706 | Tabart et al. | May 2011 | B2 |
7994185 | Rheault | Aug 2011 | B2 |
8067434 | Ibrahim et al. | Nov 2011 | B2 |
8067638 | Kai et al. | Nov 2011 | B2 |
8143271 | Ibrahim et al. | Mar 2012 | B2 |
8198273 | Ibrahim et al. | Jun 2012 | B2 |
8329724 | Hildbrand et al. | Dec 2012 | B2 |
8415469 | Ibrahim et al. | Apr 2013 | B2 |
8470818 | Ibrahim et al. | Jun 2013 | B2 |
8530661 | Hildbrand et al. | Sep 2013 | B2 |
20010008765 | Shinoki et al. | Jul 2001 | A1 |
20010012537 | Anderson et al. | Aug 2001 | A1 |
20010014448 | Chappa et al. | Aug 2001 | A1 |
20010014449 | Nerenberg et al. | Aug 2001 | A1 |
20010016322 | Caren et al. | Aug 2001 | A1 |
20010018642 | Balaban et al. | Aug 2001 | A1 |
20010019827 | Dawson et al. | Sep 2001 | A1 |
20020028809 | Imoto et al. | Mar 2002 | A1 |
20030003004 | Stones et al. | Jan 2003 | A1 |
20030219489 | Curatolo et al. | Nov 2003 | A1 |
20040002534 | Lipson et al. | Jan 2004 | A1 |
20040022534 | Amano et al. | Feb 2004 | A1 |
20040077595 | Cheng et al. | Apr 2004 | A1 |
20040142864 | Bremer et al. | Jul 2004 | A1 |
20040167030 | Bernotas et al. | Aug 2004 | A1 |
20040180947 | Kayakiri et al. | Sep 2004 | A1 |
20050014942 | Maruyama et al. | Jan 2005 | A1 |
20050026792 | Cartwright | Feb 2005 | A1 |
20050085463 | Weiner et al. | Apr 2005 | A1 |
20050154014 | Bloxham et al. | Jul 2005 | A1 |
20050164300 | Artis et al. | Jul 2005 | A1 |
20050170431 | Ibrahim et al. | Aug 2005 | A1 |
20050256151 | Salom et al. | Nov 2005 | A1 |
20060018726 | Hall | Jan 2006 | A1 |
20060024361 | Odidi et al. | Feb 2006 | A1 |
20060035898 | Arnold et al. | Feb 2006 | A1 |
20060058339 | Ibrahim et al. | Mar 2006 | A1 |
20060058340 | Ibrahim et al. | Mar 2006 | A1 |
20060183758 | Beard et al. | Aug 2006 | A1 |
20070032519 | Zhang et al. | Feb 2007 | A1 |
20070049615 | Ibrahim et al. | Mar 2007 | A1 |
20070066641 | Ibrahim et al. | Mar 2007 | A1 |
20070072862 | Dimauro et al. | Mar 2007 | A1 |
20070218138 | Bittorf et al. | Sep 2007 | A1 |
20070287711 | Arnold et al. | Dec 2007 | A1 |
20080167338 | Spevak et al. | Jul 2008 | A1 |
20080176892 | Heinrich et al. | Jul 2008 | A1 |
20080188514 | Wu et al. | Aug 2008 | A1 |
20080207700 | Werz et al. | Aug 2008 | A1 |
20090005356 | Blaney et al. | Jan 2009 | A1 |
20090076046 | Zhang et al. | Mar 2009 | A1 |
20090143352 | Arnold et al. | Jun 2009 | A1 |
20090306056 | Arnold et al. | Dec 2009 | A1 |
20100310659 | Desai et al. | Dec 2010 | A1 |
20120022258 | Brumsted et al. | Jan 2012 | A1 |
20120053177 | Ibrahim et al. | Mar 2012 | A1 |
20120122860 | Visor et al. | May 2012 | A1 |
20120245174 | Ibrahim et al. | Sep 2012 | A1 |
20130261117 | Ibrahim et al. | Oct 2013 | A1 |
20130303534 | Ibrahim et al. | Nov 2013 | A1 |
Number | Date | Country |
---|---|---|
2550361 | Jul 2005 | CA |
2413258 | Oct 1975 | DE |
0 148 725 | Jul 1985 | EP |
0 154 734 | Sep 1985 | EP |
0 344 603 | Dec 1989 | EP |
0 465 970 | Jan 1992 | EP |
0 580 860 | Feb 1994 | EP |
0 596 406 | May 1994 | EP |
0 870 768 | Oct 1998 | EP |
0 901 786 | Mar 1999 | EP |
0 988 863 | Mar 2000 | EP |
1 057 826 | Dec 2000 | EP |
1 267 111 | Dec 2002 | EP |
1 368 001 | Oct 2005 | EP |
1 749 829 | Feb 2007 | EP |
2 264 804 | Oct 1975 | FR |
1 198 301 | Jul 1970 | GB |
1 451 299 | Sep 1976 | GB |
2 292 143 | Feb 1996 | GB |
2 292 145 | Feb 1996 | GB |
2 298 198 | Aug 1996 | GB |
2 299 581 | Oct 1996 | GB |
6-135946 | May 1994 | JP |
10-130269 | May 1998 | JP |
11-284336 | Oct 1999 | JP |
2001-278886 | Oct 2001 | JP |
2003-73357 | Mar 2003 | JP |
WO-9313099 | Jul 1993 | WO |
WO-9414808 | Jul 1994 | WO |
WO-9420459 | Sep 1994 | WO |
WO-9420497 | Sep 1994 | WO |
WO-9504742 | Feb 1995 | WO |
WO-9507910 | Mar 1995 | WO |
WO-9528387 | Oct 1995 | WO |
WO-9600226 | Jan 1996 | WO |
WO-9605200 | Feb 1996 | WO |
WO-9611929 | Apr 1996 | WO |
WO-9617958 | Jun 1996 | WO |
WO-9618738 | Jun 1996 | WO |
WO-9638131 | Dec 1996 | WO |
WO-9703967 | Feb 1997 | WO |
WO-9746313 | Dec 1997 | WO |
WO-9746558 | Dec 1997 | WO |
WO-9749703 | Dec 1997 | WO |
WO-9806433 | Feb 1998 | WO |
WO-9822457 | May 1998 | WO |
WO-9847899 | Oct 1998 | WO |
WO-9858935 | Dec 1998 | WO |
WO-9900386 | Jan 1999 | WO |
WO-9909217 | Feb 1999 | WO |
WO-9932433 | Jul 1999 | WO |
WO-9951231 | Oct 1999 | WO |
WO-9951232 | Oct 1999 | WO |
WO-9951233 | Oct 1999 | WO |
WO-9951234 | Oct 1999 | WO |
WO-9951595 | Oct 1999 | WO |
WO-9951596 | Oct 1999 | WO |
WO-9951773 | Oct 1999 | WO |
WO-0009162 | Feb 2000 | WO |
WO-0012074 | Mar 2000 | WO |
WO-0012514 | Mar 2000 | WO |
WO-0017202 | Mar 2000 | WO |
WO-0029411 | May 2000 | WO |
WO-0053582 | Sep 2000 | WO |
WO-0055153 | Sep 2000 | WO |
WO-0064898 | Nov 2000 | WO |
WO-0071506 | Nov 2000 | WO |
WO-0071537 | Nov 2000 | WO |
WO-0075139 | Dec 2000 | WO |
WO-0109121 | Feb 2001 | WO |
WO-0124236 | Apr 2001 | WO |
WO-0129036 | Apr 2001 | WO |
WO-0146196 | Jun 2001 | WO |
WO-0160822 | Aug 2001 | WO |
WO-0162255 | Aug 2001 | WO |
WO-0174786 | Oct 2001 | WO |
WO-0198299 | Dec 2001 | WO |
WO-0200657 | Jan 2002 | WO |
WO-0218346 | Mar 2002 | WO |
WO-02083175 | Oct 2002 | WO |
WO-02085896 | Oct 2002 | WO |
WO-02102783 | Dec 2002 | WO |
WO-03000258 | Jan 2003 | WO |
WO-03000267 | Jan 2003 | WO |
WO-03003004 | Jan 2003 | WO |
WO-03004472 | Jan 2003 | WO |
WO-03006459 | Jan 2003 | WO |
WO-03008422 | Jan 2003 | WO |
WO-03011868 | Feb 2003 | WO |
WO-03020698 | Mar 2003 | WO |
WO-03028724 | Apr 2003 | WO |
WO-03037862 | May 2003 | WO |
WO-03051838 | Jun 2003 | WO |
WO-03064413 | Aug 2003 | WO |
WO-03068221 | Aug 2003 | WO |
WO-03082289 | Oct 2003 | WO |
WO-03082868 | Oct 2003 | WO |
WO-03082869 | Oct 2003 | WO |
WO-03087087 | Oct 2003 | WO |
WO-03101990 | Dec 2003 | WO |
WO-2004005283 | Jan 2004 | WO |
WO-2004009600 | Jan 2004 | WO |
WO-2004009601 | Jan 2004 | WO |
WO-2004014369 | Feb 2004 | WO |
WO-2004016609 | Feb 2004 | WO |
WO-2004016610 | Feb 2004 | WO |
WO-2004024895 | Mar 2004 | WO |
WO-2004052880 | Jun 2004 | WO |
WO-2004054581 | Jul 2004 | WO |
WO-2004056830 | Jul 2004 | WO |
WO-2004065393 | Aug 2004 | WO |
WO-2004065394 | Aug 2004 | WO |
WO-2004069138 | Aug 2004 | WO |
WO-2004074286 | Sep 2004 | WO |
WO-2004078756 | Sep 2004 | WO |
WO-2004078923 | Sep 2004 | WO |
WO-2004101565 | Nov 2004 | WO |
WO-2005028475 | Mar 2005 | WO |
WO-2005028624 | Mar 2005 | WO |
WO-2005030128 | Apr 2005 | WO |
WO-2005034869 | Apr 2005 | WO |
WO-2005044181 | May 2005 | WO |
WO-2005058891 | Jun 2005 | WO |
WO-2005062795 | Jul 2005 | WO |
WO-2005063746 | Jul 2005 | WO |
WO-2005063747 | Jul 2005 | WO |
WO-2005066347 | Jul 2005 | WO |
WO-2005082367 | Sep 2005 | WO |
WO-2005085244 | Sep 2005 | WO |
WO-2005086904 | Sep 2005 | WO |
WO-2005092896 | Oct 2005 | WO |
WO-2005095400 | Oct 2005 | WO |
WO-2005103050 | Nov 2005 | WO |
WO-2005115363 | Dec 2005 | WO |
WO-2005115374 | Dec 2005 | WO |
WO-2006004984 | Jan 2006 | WO |
WO-2006009755 | Jan 2006 | WO |
WO-2006009797 | Jan 2006 | WO |
WO-2006010637 | Feb 2006 | WO |
WO-2006010637 | Feb 2006 | WO |
WO-2006015123 | Feb 2006 | WO |
WO-2006015124 | Feb 2006 | WO |
WO-2006063167 | Jun 2006 | WO |
WO-2006114180 | Nov 2006 | WO |
WO-2006114520 | Nov 2006 | WO |
WO-2006114520 | Nov 2006 | WO |
WO-2006127587 | Nov 2006 | WO |
WO-2006137376 | Dec 2006 | WO |
2007002325 | Jan 2007 | WO |
2007002433 | Jan 2007 | WO |
2007002325 | Jan 2007 | WO |
WO-2007002325 | Jan 2007 | WO |
WO-2007002433 | Jan 2007 | WO |
WO-2007009799 | Jan 2007 | WO |
WO-2007013896 | Feb 2007 | WO |
WO-2007013896 | Feb 2007 | WO |
WO-2007022380 | Feb 2007 | WO |
WO-2007022380 | Feb 2007 | WO |
WO-2007106236 | Sep 2007 | WO |
WO-2007106236 | Sep 2007 | WO |
WO-2008058341 | May 2008 | WO |
WO-2008064265 | May 2008 | WO |
WO-2008064265 | May 2008 | WO |
WO-2008065417 | Jun 2008 | WO |
WO-2008079903 | Jul 2008 | WO |
WO-2008079906 | Jul 2008 | WO |
WO-2008079909 | Jul 2008 | WO |
WO-2008138755 | Nov 2008 | WO |
WO-2008138755 | Nov 2008 | WO |
WO-2009012283 | Jan 2009 | WO |
WO-2009012791 | Jan 2009 | WO |
2009016460 | Feb 2009 | WO |
WO-2009111277 | Sep 2009 | WO |
WO-2009111277 | Sep 2009 | WO |
WO-2009111278 | Sep 2009 | WO |
WO-2009111278 | Sep 2009 | WO |
WO-2009111279 | Sep 2009 | WO |
WO-2009111280 | Sep 2009 | WO |
WO-2010114928 | Oct 2010 | WO |
WO-2010114928 | Oct 2010 | WO |
Entry |
---|
Intl Search Report for PCT/EP2010/061079 dated Feb. 17, 2011. |
International Search Report mailed on Dec. 17, 2012 for PCT Patent Application No. PCT/EP2011/062207 filed on Jul. 18, 2011, eight pages. |
Written Opinion of the International Searching Authority mailed on Dec. 17, 2012 for PCT Patent Application No. PCT/EP2011/062207 filed on Jul. 18, 2011, ten pages. |
Kumar, V. et al. (Dec. 4, 1992). “Synthesis of 7-Azaindole and 7-Azaoxindole Derivatives Through a Palladium-Catalyzed Cross-Coupling Reaction,” Journal of Organic Chemistry 57(25):6995-6998. |
Pillard, C. et al. (May 2008). “Synthesis of 4-,5- and 6-Benzoylated 7-Azaindoles,” Synthesis 13:2049-2054. |
Satoh, M. et al. (Apr. 1987). “Palladium-Catalyzed Cross-Coupling Reaction of (1-Ethoxy-1-alken-2-yl)Boranes with Ortho-Functionalized lodoarenes. A Novel and Convenient Synthesis of Benzo-Fused Heteroaromatic Compounds,” Synthesis 373-377. |
Whelligan, D.K. et al. (2010, e-pub. Dec. 1, 2009). “Two-Step Synthesis of Aza- and Diazaindoles from Chloroamino-N-Heterocycles Using Ethoxyvinylborolane,” J. Org. Chem. 75(1):11-15. |
Zhao, S-B. et al. (2010, e-pub. Dec. 31, 2009). “New Bimetallic Reactivity in Pt2II,II/Pt2IV,IV Transformation Mediated by a Benzene Ring,” Organometallics 29(4): 998-1003. |
Allegretti et al. (2001). “Palladium-Catalysed Functionalisation at 4- and 6-Position of the 7-Azaindole System,” Synlett 5:609-612. |
Al-Obeidi et al. (1998). “Peptide and Peptidomimetic Libraries,” Mol. Biotechnol. 9(3):205-223. |
Alvarez et al. (1999). “Synthesis of 3-Aryl- and 3-Heteroaryl-7-Azaindoles” Synthesis 4:615-620. |
Anderson et al. (1998). “Cooperative Catalyst Effects in Palladium-Mediated Cyanation Reactions of Aryl Halides and Triflates,” J. Org. Chem. 63:8224-8228. |
Antonini et al. (1982). “Synthesis of 4-Amino-1-β-D-ribofuranosy1-1H-pyrrolo[2,3-b]pyridine (1-Deazatubercidin) as a Potential Antitumor Agent,” J. Med. Chem. 25:1258-1261. |
Arbiser (2007). “Why targeted therapy hasn't worked in advanced cancer,” J. Clin. Invest. 117(10):2762-2765. |
Bartlett et al. (1989). “CAVEAT: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules,” in Molecular Recognition: Chemical and Biological Problems, S.M. Roberts (ed.), Royal Society of Chemistry, pp. 182-196. |
Barton et al. (1987). “The chemistry of pentavalent organobismuth reagents. Part X. Studies on the phenylation and oxidation of phenols,” Tetrahedron 43(2):323-332. |
Bertolini et al. (1997). “A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug,” J. Med. Chem. 40:2011-2016. |
Bloom, A. et al. (1939). “The Preparation of 2-Alkylaminobenzimidazoles,” J. Org. Chem. 14(17):14-19. |
Blundell et al. (1988). “Knowledge-Based Protein Modelling and Design,” Eur. J. Biochem. 172:513-520. |
Bohm, H. (1994). “On the Use of LUDI to Search the Fine Chemicals Directory for Ligands of Proteins of Known Three-Dimensional Structure,” J. Comp. Aided Molec. Des. 8:623-632. |
Brenner et al. (1992). “Encoded Combinatorial Chemistry,” PNAS 89:5381-5383. |
Capon et al. (1989). “Designing CD4 Immunoadhesins for AIDS Therapy,” Nature 337:525-531. |
Carell et al. (1995). “New Promise in Combinatorial Chemistry: Synthesis, Characterization, and Screening of Small-Molecule Libraries in Solution,” Chem. Biol. 3:171-183. |
Chabala, J.C. (1995). “Solid-Phase Combinatorial Chemistry and Novel Tagging Methods for Identifying Leads,” Curr. Opin. Biotechnol. 6:632-639. |
Chayer, et al. (2001). “Synthesis of Carboranylpyrroles,” Tetrahedron Lett. 42(44):7759-7761. |
Chappell et al. (2011). “Ras/Raf/MEK/ERK and Pl3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health,” Oncotarget. 2(3):136-164. |
Chou, T. et al. (1984). “Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors,” Adv. Enzyme Regul. 22:27-55. |
Chou, T. et al. (1991). “Chemotherapeutic Synergism, Potentiation and Antagonism,” Encyclopedia of Human Biology, Academic Press, 2:371-379. |
Chou, T. (1991). “The Median-Effect Principle and the Combination Index for Quantitation of Synergism and Antagonism,” in Synergism and Antagonism in Chemotherapy, Chou, T. and Rideout, D.C. (eds.), San Diego, CA: Academic Press, Chapter 2, pp. 61-102. |
Clark et al. (1995). “PRO LIGAND: An Approach to De Novo Molecular Design. 1. Application to the Design of Organic Molecules,” J. Comp. Aided Molec. Design 9:13-32. |
Coe et al. (1999). “Solution-Phase Combinatorial Chemistry,” Mol. Divers. 4(1):31-38. |
Colliuod et al. (1993). “Oriented and Covalent Immobilization of Target Molecules to Solid Supports: Synthesis and Application of a Light-Activatable and Thiol-Reactive Cross-Linking Reagent,” Bioconjugate Chem. 4:528-536. |
Colman, P.M. (1994). “Structure-Based Drug Design,” Curr. Opin. Struct. Biol. 4:868-874. |
Coste et al. (1994). “Coupling N-Methylated Amino Acids Using PyBroP and PyCloP Halogenophosphonium Salts: Mechanism and Fields of Application,” J. Org. Chem. 59:2437-2446. |
Crump, M. (2002). “Inhibition of Raf Kinase in the Treatment of Acute Myeloid Leukemia,” Curr. Pharm. Design 8:(25):2243-2248. |
Curtin et al. (1998). “Discovery and Evaluation of a Series of 3-Acylindole Imidazopyridine Platelet-Activating Factor Antagonists,” J. Med. Chem. 41:74-95. |
Cwirla et al. (1990). “Peptides on Phage: A Vast Library of Peptides for Identifying Ligands,” Biochemistry 87:6378-6382. |
Das-Gupta et al. (1941). “Acridine Derivatives, Part IV,” J. Indian Chem. Soc. 18:25-28. |
Dastych et al. (1994). “Stem Cell Factor Induces Mast Cell Adhesion to Fibronectin,” J. Immunol. 152:213-219. |
Demetri (2001). “Targeting c-kit mutations in solid tumors: Scientific rationale and novel therapeutic options,” Seminars in Oncology 28(5)(Suppl. 17)19-26. |
Dewar et al. (2005). “Inhibition of c-fms by Imatinib Expanding the Spectrum of Treatment,” Cell Cycle 4(7):851-853. |
Dolle et al. (1999). “Comprehensive Survey of Combinatorial Library Synthesis: 1998,” J. Comb. Chem. 1(4):235-282. |
Doyle et al. (1979). “Alkyl Nitrite-metal halide Deamination Reactions. 6. Direct Synthesis of Arenediazonium Tetrafluoroborate Salts from Aromatic Amines, tert-Butyl Nitrite, and Boron Trifluoride Etherate in Anhydrous Media,” J. Org. Chem. 44(9):1572-1574. |
Dube et al. (1999). “Reductive N-Alkylation of Amides, Carbamates and Ureas,” Tetrahedron Lett. 40:2295-2298. |
Dutcher et al. (1951). “Studies of the C11H8N2OS Degradation Product of Gliotoxin,” J. Am. Chem. Soc. 73:4139-4141. |
Eklund et al. (2003). “Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvements in three refractory cases,” Annals of Medicine 35:362-367. |
Eliseev et al. (1999). “Dynamic Combinatorial Chemistry: Evolutionary Formation and Screening of Molecular Libraries,” Current Topics in Microbiology & Immunology 243:159-172. |
Enjalbal et al. (2000). “Mass Spectrometry in Combinatorial Chemistry,” Mass Spectrom. Rev. 19:139-161. |
Felder, E.R. (1994). “The Challenge of Preparing and Testing Combinatorial Compound Libraries in the Fast Lane, at the Front End of Drug Development,” Chimia 48:531-541. |
Fischer et al. (2007). “Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): What have we learned so far?,” Cancer Treatment Reviews 33(4):391-406. |
Franz et al. (1973). “Sulfuranes. X. A Reagent for the Facile Cleavage of Secondary Amides.” J. Am. Chem. Soc. 95(6):2017-2019. |
Friesen et al. (2008). “Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview,” Molecular Pharmaceutics 5(6):1003-1019. |
Gallop et al. (1994). “Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries,” J. Med. Chem. 37:1233-1251. |
Gassman et al. (1973). “Specific ortho substitution of aromatic heterocyclic amines. Conversions of 2-aminopyridines,” J. Am. Chem. Soc. 95(13):4453-4455. |
Ghebre-Sellassie, I. et al. (2003). “Film, Sheet, and Laminates,” Chapter 12 in Pharmaceutical Extrusion Technology, Marcel Dekker, Inc., New York, Basel, CRC Press, pp. 225-244. |
Girgis, N. et. al. (1989). “The Synthesis of 5-Azaindoles by Substitution-Rearrangement of 7-Azaindoles upon Treatment with Certain Primary Amines,” J. Heterocyclic Chem. 26:317-325. |
Gordon et al. (1972). “Detection of Peroxides and Their Removal,” in The Chemist's Companion: A Handbook of Practical Data, Techniques, and References, p. 437. |
Gordon et al. (1994). “Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions,” J. Med. Chem. 37:1385-1401. |
Gravert et al. (1997). “Synthesis on Soluble Polymers: New Reactions and the Construction of Small Molecules,” Curr. Opin. Chem. Biol. 1:107-113. |
Guida, W. (1994). “Software for Structure-Based Drug Design,” Curr. Opin. Struct. Biol. 4:777-781. |
Hands et al. (Jul. 1996). “A Convenient Method for the Preparation of 5-, 6- and 7-Azaindoles and Their Derivatives,” Synthesis 877-882. |
Hayashi et al. (1984). “Dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium-(II): An Effective Catalyst for Cross-Coupling of Secondary and Primary Alkyl Grignard and Alkylzinc Reagents with Organic Halides,” J. Am. Chem. Soc. 106:158-163. |
Haydock et al. (1984). “Analogues of clofibrate and clobuzarit containing fluorine in the side chains,” Eur. J. Med. Chem. 19:205-214. |
Heacock et al. (1960). “Orientation and Relative Reaction Rate Factors in Aromatic Substitution by the Benzenesulfonimido Radical,” J. Am. Chem. Soc. 82:3460-3463. |
Heinrich, M.C. et al. (2002). “Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies,” J. Clin. Oncol. 20(6):1692-1703. |
Hoffmann, R.V. (1981/1990). “m-Trifluoromethylbenzenesulfonyl Chloride,” Organic Syntheses Coll. vol. 7, p. 508; vol. 60, p. 121. |
Houghten et al. (1991). “Generation and Use of Synthetic Peptide Combinatorial Libraries for Basic Research and Drug Discovery,” Nature 354:84-86. |
Houghten, R. (2000). “Parallel Array and Mixture-Based Synthetic Combinatorial Chemistry: Tools for the Next Millennium,” Annu. Rev. Pharmacol. Toxicol. 40:273-282. |
Houghten, R. (1993). “Peptide Libraries: Criteria and Trends,” Trends Genet. 9:235-239. |
Ibrahim et al. (2007). Caplus, pp. 11300, two pages. |
Jarugula et al. (1997). “Nonlinear pharmacokinetics of 5-fluorouracil in rats,” J. Pharm. Sci. 86(6):756-757. |
Jones et al. (1984). “Antiestrogens. 2. Structure-Activity Studies in a Series of 3-Aroyl-2-arylbenzo[b]thiophene Derivatives Leading to [6-Hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl][4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with Only Minimal Intrinsic Estrogenicity,” J. Med. Chem. 27:1057-1066. |
Jones, R.J. (1997). “Biology and treatment of chronic myeloid leukemia,” Curr. Opin. Onc. 9:3-7. |
Joseph-McCarthy, D. (1999). “Computational Approaches to Structure-Based Ligand Design,” Pharmacology & Therapeutics 84:179-191. |
Katritzky et al. (2003). “Regiospecific C-Acylation of Pyrroles and Indoles Using N-Acylbenzotriazoles,” J. Org. Chem. 68:5720-5723. |
Kim et al. (2000). “A Merger of Rational Drug Design and Combinatorial Chemistry: Development and Application of Peptide Secondary Structure Mimetics,” Comb. Chem. High Throughput Screen. 3:167-183. |
Kim et al. (2002). “Preparation of 2-anilino-4-indolylpyrimidines as tyrosine kinase inhibitors,” 138:55974 (abstract). |
Kirkpatrick et al. (1999). “Structure-Based Drug Design: Combinatorial Chemistry and Molecular Modeling,” Comb. Chem. High Throughput Screen. 2:211-221. |
Kitamura et al. (2003). “Synthesis of Quinolines and 2H-Dihydropyrroles by Nucleophilic Substitution at the Nitrogen Atom of Oxime Derivatives,” Synthesis 15:2415-2426. |
Kline et al. (1986). “Studies by 1H Nuclear Magnetic Resonance and Distance Geometry of the Solution Conformation of the x-Amylase Inhibitor Tendamistat,” J. Mol. Biol. 189:377-382. |
Komoyira, S. et al. (2004). “Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as a factor Xa inhibitors: SAR study of S1 and aryl binding sites,” Bioorg. Med. Chem. 12:2099. |
Konno et al. (2006). “Influence of Different Polymers on the Crystallization Tendency of Molecularly Dispersed Amorphous Felodipine,” J. Pharm. Sci. 95(12):2692-2705. |
Kundu et al. (1999). “Combinatorial Chemistry: Polymer Supported Synthesis of Peptide and Non-Peptide Libraries,” in Progress in Drug Research, Jucker, E. (ed.), Springer Verlag AG, 53:89-156. |
Kuntz et al. (1994). “Structure-Based Molecular Design,” Acc. Chem. Res. 27:117-123. |
Lam et al. (1991). “A New Type of Synthetic Peptide Library for Identifying Ligand-Binding Activity,” Nature 354:82-84. |
Langham et al. (1941). “Metalation and Halogen-Metal Interconversion Reactions of Some Halogenated Phenyl Ethers,” J. Am. Chem. Soc. 63:545-549. |
Lebl et al. (1995). “One-Bead-One-Structure Combinatorial Libraries,” Biopolymers 37:177-198. |
Leuner, C. et al. (2000). “Improving drug solubility for oral delivery using solid dispersions,” Eur. J. Pharm. Biopharm. 50:47-60. |
Lipinski et al. (1997). “Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings,” Adv. Drug Deliv. Rev. 23:3-25. |
Liu et al. (2006). “Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5,” Cancer Res. 66:11852-11858. |
Ma et al. (2000). “Indolinone Derivatives Inhibit Constitutively Activated KIT Mutants and Kill Neoplastic Mast Cells,” J. Invest. Dermatol. 114:392-394. |
Ma et al. (2002). “The c-kit mutation causing human mastocytosis is resistant to ST1571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinase and those with regulatory-type mutations,” Blood 99:1741-1744. |
Madden, et al. (1994). “Synthetic Combinatorial Libraries: Views on Techniques and Their Application,” Perspectives in Drug Discovery and Design 2:269-285. |
Madhusudan et al. (2004). “Tyrosine kinase inhibitors in cancer therapy,” Clin. Biochem. 37(7):618-635. |
Markiewicz et al. (2000). “Synthetic Oligonucleotide Combinatorial Libraries and Their Applications,” II Farmaco 55:174-177. |
Martin, Y. (1991). “Computer-Assisted Rational Drug Design,” Methods Enzymol. 203:587-613. |
Matsumoto et al. (1999). “Physical properties of solid molecular dispersions of indomethacin with poly(vinyl)pyrrolidinone and poly(vinylpyrrolidinone-co-vinyl-acetate) in relation to indomethacin crystallization,” Pharm. Res. 16(11):1722-1728. |
Mazeas et al. (1999). “Synthesis of New Melatoninergic Ligands Including Azaindole Moiety,” Heterocycles 50(2):1065-1080. |
McPherson, A. (1990). “Current Approaches to Macromolecular Crystallization,” Eur. J. Biochem. 189:1-23. |
Merour et al. (2001). “Synthesis and Reactivity of 7-Azaindoles (1H-Pyrrolo[2,3-b]pyridine),” Current Organic Chemistry 5:471-506. |
Merritt, A.T. (1998). “Solution Phase Combinatorial Chemistry,” Comb. Chem. High Throughput Screen. 1(2):57-72. |
Meula Pomeda et al. (2002). “Efecto de codisolventes y dispersiones solidas de polivinilpirrolidona K-30 en la solubilidad del tiabendazol,” 86 VI Congreso SEFIG y 3as Jornadas TF, pp. 85-87 (with English translation of Introduction). |
Miller et al. (1994). “FLOG: A System to Select ‘Quasi-Flexible’ Ligands Complementary to a Receptor of Known Three-Dimensional Structure,” J. Comp.-Aided Mol. Des. 8:153-174. |
Minakata et al. (1992). “Functionalization of 1H-Pyrrolo[2,3-b]pyridine.” Bull. Chem. Soc. Japan 65(11):2992-2997. |
Minakata et al. (Jul. 1992). “Regioselective Functionalization of 1H-Pyrrolo[2,3-b]pyridine via its N-Oxide,” Synthesis pp. 661-663. |
Miyaura et al. (1995). “Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds,” Chem. Rev. 95:2457-2483. |
Mokhtari et al. (2010). “Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes,” Clin. Sci. 118(4):241-247. |
Mol et al. (2004). “Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase,” J. Biol. Chem. 279:31655-31663. |
Nagafuji et al. (1996). “A General Synthesis of Pyrroles and Fused Pyrrole Systems from Ketones and Amino Acids,” J. Org. Chem. 61:4999-5003. |
Nahm et al. (1981). “N-Methoxy-N-Methylamides as Effective Acylating Agents,” Tetrahedron Lett. 22(39):3815-3818. |
Nakai et al. (1988). “New Potent Antagonists of Leuokotrienes C4 and D4. 1. Synthesis and Structure-Activity Relationships,” J. Med. Chem. 31:84-91. |
Neidle et al. (1991). “Molecular Modeling to Study DNA Intercalation by Anti-Tumor Drugs,” Methods Enzymol. 203:433-458. |
Ng et al. (1995). “Engineering Protein-Lipid Interactions: Targeting of Histidine-Tagged Proteins to Metal-Chelating Lipid Monolayers,” Langmuir 11:4048-4055. |
Olah et al. (1984). “Synthetic Methods and Reactions: Part 209. Improved Preparation of Aldehydes and Ketones from N,N-Dimethylamides and Grignard Reagents,” Synthesis pp. 228-230. |
Ottoni et al. (1998). “Efficient and Simple Methods for the Introduction of the Sulfonyl, Acyl and Alkyl Protecting Groups on the Nitrogen of Indole and its Derivatives,” Tetrahedron 54:13915-13928. |
Owicki et al. (1997). “Application of Fluorescence Polarization Assays in High-Throughput Screening,” Genetic Engineering News 17:28. |
Panitumumab PiCCA Study (Panitumumab in Combination with Cisplatin/Gemcitabine) (2012). National Cancer Institute at the National Institutes of Health, located at http://clinicaltrials.gov/ct2/show/NCT01320254, last visited on Dec. 16, 2013, 5 pages. |
Parker et al. (2000). “Development of High Throughput Screening Assays Using Fluorescence Polarization: Nuclear Receptor-Ligand-Binding and Kinase/Phosphatase Assays,” J. Biomol. Screen. 5:77-88. |
Patani et al. (1996). “Bioisosterism: A rational approach in drug design,” Chem. Rev. 96:3147-3176. |
Perrin, D.M. (2000). “Nucleic Acids for Recognition and Catalysis: Landmarks, Limitations, and Looking to the Future,” Comb. Chem. High Throughput Screen. 3:243-269. |
Pflugrath et al. (1986). “Crystal Structure Determination, Refinement and the Molecular Model of the α-Amylase Inhibitor Hoe-467A,” J. Mol. Biol. 189:383-386. |
Pierce et al. (1942). “Local anaesthetics. I. Beta-Monoalkylaminoethyl Esters of Alkoxybenzoic Acids,” J. Am. Chem. Soc. 64:1691-1694. |
Plunkett et al. (1995). “A Silicon-Based Linker for Traceless Solid-Phase Synthesis,” J. Org. Chem. 60:6006-6007. |
Remington. (1995). “Preformulation,” Chapter 83 in Remington: The Science and Practice of Pharmacy, Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Co., Easton, PA, vol. 2, pp. 1457-1462. |
Robison et al. (1955). “7-Azaindole. I. Synthesis and Conversion to 7-Azatryptophan and Other Derivatives,” J. Am. Chem. Soc. 77:457-460. |
Rodan, G. et al. (2000). “Therapeutic Approaches to Bone Diseases,” Science 289:1508-1514. |
Saify et al. (1994). “Synthesis of some 7-azaindole derivatives: their cytotoxicity and antibacterial activity,” Pakistan Journal of Scientific and Industrial Research 37(10):439-441. |
Saiki, R. (1990). “Amplification of Genomic DNA,” in PCR Protocols: A Guide to Methods and Applications, Academic Press, Inc.: San Diego, CA 2:13-20. |
Sathornsumetee et al. (2006). “AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma,” Cancer Res. 66:8722-8730. |
Sawada et al. (2001). “4-(Benzoylindolizinyl)butyric acids: Novel nonsteroidal inhibitors of steroid 5α-reductase. III,” Chem. Pharm. Bull. 49(7):799-813. |
Schiemann et al. (1943). “p-Fluorobenzoic Acid,” Org. Synth. Coll. vol. 2, 299, 4 total pages. |
Schneller et al. (1980). “Synthesis of 4-Amino-1H-Pyrrolo[2,3-b]pyridine (1,7-Dideazaadenine) and 1H-Pyrrolo[2,3-b]pyridin-4-ol (1,7-Dideazahypoxanthine),” J. Org. Chem. 45:4045-4048. |
Schweizer et al. (1999). “Combinatorial Synthesis of Carbohydrates,” Curr. Opin. Chem. Biol. 3(3):291-298. |
Shah et al. (2006). “Analytical Techniques for Quantification of Amorphous/Crystalline Phases in Pharmaceutical Solids,” J. Pharm. Sci. 95(8):1641-1665. |
Shan et al. (1997). “Prodrug strategies based on intramolecular cyclization reactions,” J. Pharm. Sci. 86(7):765-767. |
Song et al. (2002). “Isomerism of Bis(7-azaindolyl)methane.” Org. Lett. 4:23:4049-4052 and Supporting information pp. 1-15. |
Sorafenib Tosylate. (2012). National Cancer Institute at the National Institutes of Health, located at <http://www.cancer.gov/cancertopics/druginfo/sorafenibtosylate>, last visited on Dec. 16, 2013, two pages. |
Su et al. (1960). “Synthesis of Bromo-substituted Indoxyl Esters for Cytochemical Demonstration of Enzyme Activity,” J. Am. Chem. Soc. 82:1187-1189. |
Sun, C. (1999). “Recent Advances in Liquid-Phase Combinatorial Chemistry,” Comb. Chem. High Throughput Screen. 2:299-318. |
Sun, C. (1999). “Design, Synthesis and Evalutions of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, PGF, and PDGF Receptor Tyrosine Kinases,” J. Med. Chem. 42:5120-5130. |
Tanno et al. (2004). “Evaluation of Hypromellose Acetate Succinate (HPMCAS) as a Carrier in Solid Dispersions,” Drug Dev. Ind. Pharm. 30(1):9-17. |
Thibault et al. (2003). “Concise and Efficient Synthesis of 4-Fluoro-1H-pyrrolo[2,3-b]pyridine,” Org. Lett. 5:5023-5025. |
Thomas et al. (2001). “Light-Emitting Carbazole Derivatives: Potential Electroluminescent Materials,” J. Am. Chem. Soc. 123:9404-9411. |
Toste et al. (1995). “A Versatile Procedure for the Preparation of Aryl Thiocyanates Using N-Thiocyanatosuccinimide (NTS),” Synth. Commun. 25(8):1277-1286. |
Uritskaya et al. (1973). Azaindole derivatives. XLIII. Synthesis of 1-acety1-4-methy1-7-azatryptamine, STN Accession No. 1974:27133; Document No. 80:27133; Abstract of Khimiya Geterotsiklichenskikh Soedinenii 10:1370-1373. |
Vachon et al. (1997). “The influence of microencapsulation using Eudragit RS100 on the hydrolysis kinetics of acetylsalicylic acid,” J. Microencapsulation 14:281-301. |
Vandelli et al. (1993). “Analysis of release data in the evaluation of the physical state of progesterone in matrix systems,” J. Microencapsulation 10(1):55-65. |
Weber, P. (1991). “Physical Principles of Protein Crystallization,” Adv. Protein Chem. 41:1-36. |
Wells et al. (2009). “Targeting the RET Pathway in Thyroid Cancer,” Clin. Cancer Res. 15(23):7119-7123. |
Wendt et al. (2004). “Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution,” J. Med. Chem. 47(2):303-324. |
Wessjohann, L. (2000). “Synthesis of Natural-Product-Based Compound Libraries,” Curr. Opin. Chem. Biol. 4:303-309. |
Yakhontov et al. (1965). “Derivatives of 7-azaindole. XV. Electrophilic substitution of 4-methyl-7-azaindole and its derivatives.” Zhurnal Obshchei Khimii 1(11):2032-2040. (English abstract only). |
Yang, et al. (1992). “Synthesis of Some 5-Substituted Indoles,” Heterocycles 34:1169-1175. |
Yeung et at. (2002). “Friedel-Crafts acylation of indoles in acidic imidazolium chloroaluminate ionic liquid at room temperature,” Tetrahedron Lett. 43(33):5793-5795. |
Zanon et al. (2003). “Copper-Catalyzed Domino Halide Exchange-Cyanation of Aryl Bromides,” J. Am. Chem. Soc. 125:2890-2891. |
Zhang et al. (2002). “An effective procedure for the acylation of azaindoles at C-3,” J. Org. Chem. 67(17):6226-6227 and p. S1-S30. |
Number | Date | Country | |
---|---|---|---|
20130005761 A1 | Jan 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12843908 | Jul 2010 | US |
Child | 13613017 | US |